Trillium Therapeutics Inc (TRIL)

[NY1972]

18% of patients experienced grade 3 or worse cytokine release syndrome and 34% experienced neurological toxicity.

The toxicity involved with these therapies is significant and, generally, a place that handles toxicity well has a busy inpatient unit, experience in transplantation and an excellent ICU.

CAR T-cell therapy’s availability likely will be similar to bone marrow or stem cell transplantation

http://www.healio.com/hematology-oncology/leukemia/news/print/hemonc-today/%7Bd14fee4d-3721-4985-b229-916f7e42f5fc%7D/car-t-cells-may-transform-blood-cancer-treatment-but-concerns-remain-about-safety-availability?page=2